Loading stock data…
TMCI
$2.53+0.23 (+10.24%)
Market ClosedLast close May 13
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Treace Medical Concepts, Inc. in the Healthcare sector is trading at $2.53. Wall Street consensus targets $4.00 (3 analysts), implying a +58.1% move over the next 12 months. The stock is currently 67% below its 52-week high of $7.78, remaining 33.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 77 is overbought against a weak tape. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
Ecosystem Influences
Sell-side targets imply +58.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 77 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$2.53
Potential Downside
0%
Whystock Fair Value$2.53
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Hold
Mean target$4.00+58.1%
Range$2.00 – $7.00
Fundamentals
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stab...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$121.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.88
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-56.31%
Volume
Today's trading volume
796,552
Recent News
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
The market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investments still offer potential value by focusing on smaller or newer companies with strong financials. In this article, we explore three penny stocks that demonstrate financial strength and could present opportunities for investors seeking hidden value in quality companies.
Treace Medical Concepts Inc (TMCI) Q1 2026 Earnings Call Highlights: Navigating Revenue ...
Despite a 10% revenue drop, Treace Medical Concepts Inc (TMCI) focuses on new product adoption and strategic growth to overcome market challenges.
Treace Medical Concepts Q1 Earnings Call Highlights
Treace Medical Concepts (NASDAQ:TMCI) reaffirmed its full-year 2026 revenue outlook after reporting a first-quarter revenue decline, as management said new product adoption is helping drive procedure volume momentum despite pricing and mix headwinds. On the company’s first-quarter earnings call, Ch
Treace Medical Concepts (TMCI) Reports Q1 Loss, Beats Revenue Estimates
Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of +9.68% and +2.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
How The Treace Medical Concepts (TMCI) Story Is Shifting With Mixed Analyst Expectations
The latest update keeps Treace Medical Concepts' fair value estimate at US$4.25, while Street price targets now cluster around levels such as US$7 on the bullish side and US$2 to US$2.25 on the more cautious end. These shifts line up with a split analyst view, as some focus on Q4 product mix pressure and product launch timing, while others see current valuations as already reflecting a cautious setup. Read on to see how to interpret these competing narratives and track the next moves in the...